KPTI vs PRU · rev $68.5M vs rev $31.19B
Karyopharm Therapeutics Inc (KPTI) versus PRU (PRU) — a side-by-side from cached financials, not a winner call.
Karyopharm Therapeutics Inc (KPTI) is a biotechnology company listed on US.
PRU (PRU) common stock.
Latest reported KPTI revenue for 2026-06-30 was $68.5M. Net income was -$89.4M. Revenue was up 95.3% from 2026-03-31 to 2026-06-30. KPTI currently screens at market cap $205.6M.
Latest reported PRU revenue for 2026-06-30 was $31.19B. Net income was $1.58B. PRU currently screens at market cap $0.
KPTI currently screens at market cap $205.6M. PRU currently screens at market cap $0.
Not investment advice. Open the KPTI and PRU stock pages for the full models.
Not investment advice.